XML 25 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common stock
Retained earnings
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Dec. 31, 2022   18,730,380    
Beginning balance at Dec. 31, 2022 $ 562,147 $ 226,592 $ 435,085 $ (99,530)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (27,508)   (27,508)  
Share-based compensation expense 3,613 $ 3,613    
Common stock issued - Option exercise; stock grants (in shares)   92,769    
Common stock issued - Option exercise; stock grants 0      
Other comprehensive income (loss) 12,671     12,671
Dividends declared (12,220)   (12,220)  
Common stock repurchased (in shares) [1]   (13,094)    
Common stock repurchased [1] $ (316) $ (316) 0  
Ending balance (in shares) at Dec. 31, 2023 18,810,055 18,810,055    
Ending balance at Dec. 31, 2023 $ 538,387 $ 229,889 395,357 (86,859)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (144,344)   (144,344)  
Share-based compensation expense 3,430 $ 3,430    
Common stock issued - Option exercise; stock grants (in shares)   60,483    
Common stock issued - Option exercise; stock grants 0      
Other comprehensive income (loss) (342)     (342)
Common stock repurchased (in shares) [1]   (12,973)    
Common stock repurchased [1] $ (134) $ (134)    
Ending balance (in shares) at Dec. 31, 2024 18,857,565 18,857,565    
Ending balance at Dec. 31, 2024 $ 396,997 $ 233,185 $ 251,013 $ (87,201)
[1] 1) These amounts represent shares withheld from stock grants to pay for individual employee taxes on their stock grants.